About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01623349

Phase I of BKM120/Olaparib for Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Study identifier: NCT01623349
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Olaparib (AstraZeneca)

Eligibility:

  • Recurrent ovarian Cancer (high grade serous carcinoma). Prior therapy must have included platinum-based drug.
  • Metastatic triple negative breast cancer, and at least 1 chemotherapy regimen for metastatic breast cancer or developed metastatic breast cancer within 1 year of completion of adjuvant chemotherapy,

Type of study:

Phase I study

Treatment:

Escalating doses of oral olaparib twice daily and oral BKM120 (an oral PI3 Kinase inhibitor) once daily

Study sites:

Massachusetts
Boston
Dana-Farber Cancer Institute
Contact: Brian Lasonde 617-632-3743 blasonde@partners.org
Contact: Christin Whalen, RN 617-582-7738 cwhalen@partners.org

Massachusetts General Hospital
Contact: Meghan Comeau 617-726-0491 mcomeau@mghihp.edu

Beth Israel Deaconess Medical Center
Contact: Kathryn Componeschi kcompone@bidmc.harvard.edu
Contact: Robert Shaw 617-667-5987 rdshaw@bidmc.harvard.edu

New York
New York
Memorial Sloan-Kettering Cancer Center
Contact: Sara Kravetz 646-888-4423 kravetzs@mskcc.org

Texas
Houston
MD Anderson Cancer Center
Contact: Michael Garcia, RN 713-794-1421 mgarcia@mdanderson.org

Page updated 06/13/13

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org